Welcome to the Bavarian Biotechnology Cluster

Browse our Webpage to find your partner of excellence in the Bavarian Biotech Sector.

Bavaria plays a leading role in all major areas of Biotechnology. Among them are Pharmaceutical (Diagnostics and new Therapeutics) Biotechnology, the "omics"-technologies, personalized medicine and biomarker research as well as the industrial and environmental applications of this future technology.

By interlinking business and science the Biotechnology Cluster provides a state-wide network that supports and strengthens the entire process from an original idea to a final product.

From Invention to Innovation!


The latest infos on these pages

  • Study Demonstrates Micromet's Blinatumomab Produces High Single-Agent Activity in Patients with Relapsed Acute Lymphoblastic Leukemia

    10.06.2011: Study Demonstrates Micromet's Blinatumomab Produces High Single-Agent Activity in Patients with Relapsed Acute Lymphoblastic Leukemia

    • 75% of patients achieved a complete remission, with no evidence of remaining leukemic cells in blood or bone marrow
    • Data add to a growing body of clinical evidence demonstrating blinatumomab's potential to be used across the course of the disease
    more ...

  • Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin Therapeutics

    12.04.2011: Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin Therapeutics

    Pieris AG announced today the signature of a
    collaboration and license agreement with Daiichi Sankyo Company Limited, under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets.more ...

  • Light-Harvesting Processes LHP2011

    05.04.2011: Light-Harvesting Processes LHP2011

    The third international conference "Light-Harvesting Processes LHP2011" will be held from April 10 – 14, 2011 in Staffelstein and is concerned with novel solar cells inspired by the natural process of photosynthesis. more ...

  • AMSilk Closes 5 Million Euro Financing Round

    17.03.2011: AMSilk Closes 5 Million Euro Financing Round

    AMSilk, a privately-held company specializing in the development and production of high performance materials based on spider silk, is announcing the successful completion of a 5 million Euro Series B financing round. more ...

  • A Cancer Gene Keeps Itself in Check

    18.02.2011: A Cancer Gene Keeps Itself in Check

    Scientists of the Biozentrum, University of Würzburg describe feed-back loop of the oncogene Mycmore ...

All News

Cluster Initiative Bavaria